JP2021075563A5 - - Google Patents

Download PDF

Info

Publication number
JP2021075563A5
JP2021075563A5 JP2021020446A JP2021020446A JP2021075563A5 JP 2021075563 A5 JP2021075563 A5 JP 2021075563A5 JP 2021020446 A JP2021020446 A JP 2021020446A JP 2021020446 A JP2021020446 A JP 2021020446A JP 2021075563 A5 JP2021075563 A5 JP 2021075563A5
Authority
JP
Japan
Prior art keywords
composition
oxo
composition according
fibrosis
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021020446A
Other languages
English (en)
Japanese (ja)
Other versions
JP7229285B2 (ja
JP2021075563A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2021075563A publication Critical patent/JP2021075563A/ja
Publication of JP2021075563A5 publication Critical patent/JP2021075563A5/ja
Priority to JP2023020423A priority Critical patent/JP2023065454A/ja
Application granted granted Critical
Publication of JP7229285B2 publication Critical patent/JP7229285B2/ja
Priority to JP2025002652A priority patent/JP2025061087A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021020446A 2015-05-13 2021-02-12 １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法 Active JP7229285B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023020423A JP2023065454A (ja) 2015-05-13 2023-02-14 １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法
JP2025002652A JP2025061087A (ja) 2015-05-13 2025-01-08 １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562160863P 2015-05-13 2015-05-13
US62/160,863 2015-05-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017559093A Division JP2018524274A (ja) 2015-05-13 2016-05-12 １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023020423A Division JP2023065454A (ja) 2015-05-13 2023-02-14 １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法

Publications (3)

Publication Number Publication Date
JP2021075563A JP2021075563A (ja) 2021-05-20
JP2021075563A5 true JP2021075563A5 (https=) 2022-01-11
JP7229285B2 JP7229285B2 (ja) 2023-02-27

Family

ID=56131573

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017559093A Pending JP2018524274A (ja) 2015-05-13 2016-05-12 １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法
JP2021020446A Active JP7229285B2 (ja) 2015-05-13 2021-02-12 １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法
JP2023020423A Withdrawn JP2023065454A (ja) 2015-05-13 2023-02-14 １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法
JP2025002652A Pending JP2025061087A (ja) 2015-05-13 2025-01-08 １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017559093A Pending JP2018524274A (ja) 2015-05-13 2016-05-12 １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023020423A Withdrawn JP2023065454A (ja) 2015-05-13 2023-02-14 １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法
JP2025002652A Pending JP2025061087A (ja) 2015-05-13 2025-01-08 １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法

Country Status (7)

Country Link
US (4) US10047033B2 (https=)
EP (1) EP3294282A1 (https=)
JP (4) JP2018524274A (https=)
CN (3) CN113896628A (https=)
HK (1) HK1250345A1 (https=)
MA (1) MA47141A (https=)
WO (1) WO2016181221A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9682055B2 (en) 2014-06-04 2017-06-20 Dignity Sciences Limted Pharmaceutical compositions comprising DGLA and use of same
MA47141A (fr) 2015-05-13 2019-11-06 Ds Biopharma Ltd Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation
CA3129008A1 (en) * 2015-12-18 2017-06-22 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
CN113164377A (zh) * 2018-10-18 2021-07-23 Ds生物制药有限公司 用于治疗炎性、纤维化和增生性病状的dgla和/或15-hetre
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47777B1 (en) 1978-01-23 1984-06-13 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
US5352700A (en) 1988-01-14 1994-10-04 Anders Frithz Use of essential fatty acids for the preparation of a drug for the treatment of infantile seborrheic eczema
CA1334002C (en) 1988-09-28 1995-01-17 Barry D. Sears Essential fatty acid compositions and methods for the modulation of prostaglandin levels in mammals
GB9111900D0 (en) 1991-06-03 1991-07-24 Efamol Holdings Fatty acid compositions
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
DE4238869C2 (de) 1992-11-18 1994-09-08 Wogepharm Gmbh Mittel zur Behandlung des atopischen Ekzems und anderer entzündlicher Hautkrankheiten
GB9301446D0 (en) 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
JPH09505562A (ja) 1993-10-01 1997-06-03 アール．ピー．シェーラー コーポレイション 香料を小分けして提供する方法および組成物
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
EP1762557B1 (en) 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
JP2002047176A (ja) 2000-08-04 2002-02-12 Idemitsu Technofine Co Ltd ＩｇＥ産生抑制剤
US20020188024A1 (en) 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
DE10121252A1 (de) 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
ATE291910T1 (de) 2001-05-30 2005-04-15 Laxdale Ltd Verwendung von coenzym q (ubiquinone) und eikosapentaensäure (epa) für die behandlung von non-hodgkin's lymphoma und psychiatrischen oder neurologischen erkrankungen
JP2003155233A (ja) 2001-11-16 2003-05-27 Idemitsu Technofine Co Ltd 塗布剤
KR20050083960A (ko) 2002-11-22 2005-08-26 닛폰 스이산 가부시키가이샤 고도 불포화 지방산, 그 염, 또는 그 에스테르를 함유하는외용 조성물
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
EP1711173A2 (en) 2003-12-31 2006-10-18 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
AU2005262392A1 (en) 2004-07-01 2006-01-19 Johnson & Johnson Vision Care, Inc. Compositions and methods for treating eye disorders and conditions
US7666447B2 (en) 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
US7893106B2 (en) 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
EP3581178B1 (en) 2005-02-14 2023-08-30 Suntory Holdings Limited Composition containing dihomo-(gamma)-linolenic acid (dgla) as active ingredient
JP5101894B2 (ja) 2007-01-15 2012-12-19 サントリーホールディングス株式会社 高度不飽和脂肪酸及びこれを含有する脂質の製造方法
PE20100156A1 (es) 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
US20110105510A1 (en) 2008-06-17 2011-05-05 Hiroshi Ishikawa Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
MX360979B (es) 2011-09-16 2018-11-22 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico.
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
RS57777B1 (sr) 2012-01-06 2018-12-31 Omthera Pharmaceuticals Inc Dpa-obogaćene kompozicije omega-3 polinezasićenih masnih kiselina u obliku slobodne kiseline
US20130267598A1 (en) * 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
WO2013150386A2 (en) 2012-04-04 2013-10-10 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
MX372724B (es) * 2012-12-24 2020-06-19 Qualitas Health Inc Formulaciones de acido eicosapentaenoico (epa).
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
US9889108B2 (en) * 2013-03-15 2018-02-13 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
TWI742541B (zh) 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
US9682055B2 (en) 2014-06-04 2017-06-20 Dignity Sciences Limted Pharmaceutical compositions comprising DGLA and use of same
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
MA47141A (fr) 2015-05-13 2019-11-06 Ds Biopharma Ltd Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation
CA3129008A1 (en) 2015-12-18 2017-06-22 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
CA3027867A1 (en) 2016-01-07 2017-07-13 Ds Biopharma Limited Pharmaceutical compositions comprising dgla and use of same

Similar Documents

Publication Publication Date Title
JP2021075563A5 (https=)
JP2023065454A5 (https=)
JP2021063088A5 (https=)
JP2009545527A (ja) 粘膜炎の治療用の組成物及び方法
JP2015508068A5 (https=)
US6426367B1 (en) Methods for selectively occluding blood supplies to neoplasias
US10363235B2 (en) Compositions comprising 15-HEPE and methods of treating or preventing fibrosis using same
JP2021525787A5 (https=)
JP2024149666A (ja) 肝硬変の治療のための組成物
Vineberg Restoration of coronary circulation by anastomosis
RU2013126522A (ru) Лизурид, тергурид и их производные для применения в профилактике и/или лечении фиброзных изменений
Lowry et al. Primary osteosarcoma of the heart
KR100874626B1 (ko) 담즙 분비 촉진 조성물
Sutcliffe et al. Chronic granulomatous disease
FI3886834T3 (fi) Menetelmiä nitrosyloitujen propaandiolien valmistamiseksi, niitä sisältäviä koostumuksia sekä niiden lääkinnällisiä käyttöjä
Holden et al. Late results of bronchography using Dionosil oily
ZEPPA et al. Medial degeneration and aneurysm of the hepatic artery
JP2005523317A (ja) 爪の微生物病を制御するための局所用組成物の使用
JP2007504097A5 (https=)
CN120227441B (zh) 用于动脉粥样硬化联合治疗的药物组合物
Dreizen et al. The effect of experimentally induced generalized medial arteriosclerosis on the oral vessels of the rat
JP2003504404A (ja) 抗虚血薬
JPH0541605B2 (https=)
RU2021114870A (ru) Способы получения нитрозилированных пропандиолов, композиций, содержащих такие соединения, и их клиническое применение
JP6679299B2 (ja) ニキビ治療用外用医薬組成物